OncoResponse Raises $40 Million in Series B Financing-- Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers -- -- Proceeds Will Advance Growing Portfolio of Therapeutic Candidates for Various Cancers -- SEATTLE, Wash., September 11, 2018-– OncoResponse, an immunotherapy company developing a portfolio of novel antibodies to high-value targets for the treatment of cancer, today announced the completion of a $40 million series B equity financing.